Lumira Ventures

Lumira Ventures, established in 2007, is a prominent North American venture capital firm specializing in healthcare and life sciences investments. Based in Toronto, with additional offices in Montreal, Vancouver, and Boston, the firm focuses on emerging, mid, and late-stage companies in biotechnology, biopharmaceuticals, medical devices, digital health, and consumer health sectors. Lumira Ventures invests between $5 million to $15 million, providing not only capital but also active board participation, access to funding sources, partners, and market access to maximize the value of its portfolio companies' technology pipelines. With a 30-year history, the firm has invested in over 100 healthcare companies and currently has a portfolio of 30+ active investee companies across Canada and the United States.

Daniel Hetu

Managing Director

Vasco Larcina

CFO

Alice Luo

Analyst

David Novak

Venture Partner

Suman Rao

Senior Associate

Benjamin Rovinski, Ph.D.

Managing Director

Nikhil Thatte

Principal

Peter van der Velden, MBA, M.Sc.

Founder and Managing General Partner

Baye Galligan

Director of Research

Past deals in Boston, MA

Axonis Therapeutics

Series A in 2024
Axonis Therapeutics is a biotechnology company focused on developing therapies for neurological disorders by targeting KCC2, a key mediator of inhibition in the brain. The company utilizes a proprietary discovery engine centered on the neuron-specific K-Cl cotransporter (KCC2) to address various conditions, including epilepsy and pain, as well as other central nervous system pathologies. By harnessing breakthrough research from institutions such as Boston Children’s Hospital, Harvard, and Laval University, Axonis aims to enhance the lives of individuals affected by these disorders through improved modulation of neuronal inhibition.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.